Browse studies, page 409
Page 409 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study International journal of clinical pharmacy, 2025
- Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy DEN open, 2025
- Vietnam Association of Gastroenterology (VNAGE) guideline on the management of gastroesophageal reflux disease Frontiers in medicine, 2026
- Long-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole Annals of medicine and surgery (2012), 2025
- Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Cureus, 2024
- Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach Clinical and translational science, 2024
- 2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy Journal of neurogastroenterology and motility, 2026
- Editorial: proton pump inhibition – microbial complications beyond dysbiosis Alimentary Pharmacology and Therapeutics, 2019
- Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366 Frontiers in pharmacology, 2025
- Potassium-competitive acid blocker versus proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial American heart journal, 2025
- Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial Lung, 2025
- Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial BMC Gastroenterology, 2023
- Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial Clinical and translational gastroenterology, 2023
- Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis Gut and liver, 2023
- Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which's better? World journal of gastroenterology, 2025
- Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis World journal of gastroenterology, 2022
- A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations Medicine, 2022
- A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis Clinical and translational gastroenterology, 2025
- Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects Clinical drug investigation, 2021
- Risk of Clostridioides difficile infection with potassium-competitive acid blockers: A systematic review with restricted quantitative synthesis Therapeutic Advances in Drug Safety, 2026
- Potassium-Competitive Acid Blocker–Based Triple Therapy versus Proton Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-analysis of Randomized Controlled Trials Journal of Nepalese Society of Gastroenterologists, 2026
- Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis Frontiers in pharmacology, 2023
- Second Asian Consensus Report on Functional Dyspepsia (2025): Updated Recommendations Journal of gastroenterology and hepatology, 2026
- Systematic mapping of registered interventional studies addressing the top 10 research priorities in Barrett's oesophagus and gastro-oesophageal reflux disease BMJ open gastroenterology, 2025
- Comparative efficacy of different durations and dosages of vonoprazan and amoxicillin dual therapy: a network meta-analysis of randomized controlled trials Frontiers in medicine, 2026
- Comparative efficacy and safety of fexuprazan versus esomeprazole in gastroesophageal reflux disease: a systematic review and meta-analysis Frontiers in medicine, 2026
- Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis Frontiers in Pharmacology, 2024
- Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis Helicobacter, 2024
- The Efficacy of Potassium Competitive Acid Blocker-based First-line Triple Therapy on Helicobacter pylori Eradication as Compared to Proton Pump Inhibitor-based Treatment: A Systematic Review and Meta-analysis Yakhak Hoeji, 2022
- Systematic evaluation and meta-analysis of the efficacy and tolerability of tegoprazan in an Asian population 2022
- Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials Clinics (Sao Paulo, Brazil), 2022
- Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis Journal of neurogastroenterology and motility, 2024
- Efficacy and safety of tegoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials European journal of gastroenterology & hepatology, 2026
- A randomized noninferiority trial comparing tegoprazan triple therapy and bismuth quadruple therapy for Helicobacter pylori eradication Scientific Reports, 2026
- Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial Gut and Liver, 2022
- Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study Helicobacter, 2023
- Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing Translational and Clinical Pharmacology, 2024
- Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line Helicobacter pylori Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis Microorganisms, 2024
- Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study Current Medical Research and Opinion, 2024
- S977 Comparative Efficacy and Safety of Tegoprazan vs Proton Pump Inhibitors for Erosive Esophagitis: A Meta-Analysis of Randomized Controlled Trials American Journal of Gastroenterology, 2025
- S2118 Seven-Day Tegoprazan Therapy Matches Proton Pump Inhibitors and 14-Day Therapies for H. pylor Eradication With Much Fewer Adverse Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials American Journal of Gastroenterology, 2025
- Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study Helicobacter, 2024
- Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study Expert Review of Anti-Infective Therapy, 2024
- Safety and effectiveness of tegoprazan in patients treated with dual antiplatelet therapy after drug-eluting stent implantation for acute myocardial infarction European Heart Journal, 2025
- Efficacy and Safety of Tegoprazan in Patients with Erosive Gastroesophageal Reflux Disease- A Multicountry, Prospective, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Japanese journal of gastroenterology, 2025
- The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials Therapeutic Advances in Gastroenterology, 2025
- Enzymatic kinetic resolution of an intermediate alcohol of the drug Tegoprazan using lipase from Thermomyces lanuginosus Biocatalysis and Biotransformation, 2024
- Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects Alimentary Pharmacology & Therapeutics, 2019
- Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis Research Square, 2024
- Anti-Inflammatory Therapeutic Effect of Tegoprazan in Spinal Cord-Injured Rats Discovery Medicine, 2026
- Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review PLoS ONE, 2024
- A Practical Green Synthesis of ( R )-5,7-difluorochroman-4-ol, a Key Intermediate of Tegoprazan Organic Preparations and Procedures International, 2024
- Beyond Proton Pump Inhibitors: Tegoprazan and the Emergence of Potassium-Competitive Acid Blockade International Journal of Medical & Pharmaceutical Sciences, 2026
- Polymeric solid dispersion enhances the equilibrium solubility and oral bioavailability of tegoprazan Bulletin of the Korean Chemical Society, 2023
- Development of Stability Indicating Densitometric Method for Estimation of Tegoprazan used in the Treatment of Gastroesophageal Reflux Disease Journal of Research in Pharmacy, 2026
- Non-inferiority of Tegoprazan to PPIs in H. pylori Eradication: Systematic Review and Meta-analysis Endoscopy, 2026
- Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial Journal of Neurogastroenterology and Motility, 2022
- Efficacy of Tegoprazan-Amoxicillin vs BQT therapy in the treatment of H.pylori OSF Preprints (OSF Preprints), 2026
- Evaluation of the comparative pharmacokinetic properties of a new orally disintegrating tablet of tegoprazan in healthy Korean subjects International Journal of Clinical Pharmacology and Therapeutics, 2023
- First Confirmed Case of Tegoprazan‐Induced Anaphylaxis Demonstrated by Drug Provocation Testing Case Reports in Medicine, 2026
- Advances in Peptic Ulcer Treatment: Role of Vonoprazan, Tegoprazan, Keverprazan, and Anaprazole medtigo Journal of Medicine, 2025
- Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects Translational and Clinical Pharmacology, 2019
- Tegoprazan: A Next-Generation P-CAB Redefining Acid Suppression Zenodo (CERN European Organization for Nuclear Research), 2025
- Comparative hepatic safety between tegoprazan and esomeprazole: a real-world cohort study Frontiers in Pharmacology, 2026
- The effect of potassium-competitive acid blocker tegoprazan on gastric cancer cells Journal of Clinical Oncology, 2023
- Beyond Dual Therapy: Rethinking Tegoprazan–Amoxicillin for H. pylori Journal of Gastroenterology and Hepatology, 2026
- Role of Tegoprazan in Helicobacter pylori Eradication Therapy Gut and Liver, 2022
- Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB) Organic Process Research & Development, 2024
- Determination of Enantiomeric Impurity in Tegoprazan Drug Substance by HPLC Separation Science Plus, 2024
- Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers 2020
- Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy on the healing of endoscopic submucosal dissection-induced gastric ulcer: A randomized-controlled multicenter study Endoscopy, 2025
- Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects Alimentary Pharmacology & Therapeutics, 2020
- Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer Alimentary Pharmacology & Therapeutics, 2020
- Formulation and Evaluation of Gastro-Retentive Floating Tablets of Tegoprazan International Journal of Drug Delivery Technology, 2026
- Determination of Four Related Substances in Tegoprazan by HPLC Separation Science Plus, 2025
- Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan Clinical Therapeutics, 2021
- Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility Journal of Pharmacology and Experimental Therapeutics, 2017
- Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease Alimentary Pharmacology & Therapeutics, 2021
- An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interaction Between Tegoprazan and Novel Oral Anticoagulants (NOACs) After Multiple Oral Dosing in Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2023
- An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics and Safety of IN-C004 in Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2021
- Tegoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Based Bismuth Quadruple Therapy for First-Line Helicobacter Pylori Eradication: A Prospective, Randomized, Multicenter, Superiority Study (TATH-1) ClinicalTrials.gov · COMPLETED, 2025
- A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 (Pilot) Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance ClinicalTrials.gov · COMPLETED, 2021
- The Efficacy of Potassium-competitive Acid Blocker (P-CAB) in Patients With Laryngopharyngeal Reflux Disease: a Double- Blind, Randomized, Placebo-controlled Pilot Study ClinicalTrials.gov · COMPLETED, 2023
- A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Explore the Drug Interaction of Tegoprazan or RAPA113 and Clopidogrel After Oral Administration in Healthy Male Volunteers ClinicalTrials.gov · COMPLETED, 2020
- A Randomized, Open-label, Active-controlled, Multiple Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, and Pharmacodynamics of Tegoprazan After Oral Administration in Healthy Male Volunteers ClinicalTrials.gov · COMPLETED, 2018
- A Randomized, Open-label, Single-dose Phase 1 Clinical Trial to Compare the Effect of Timing of Food on the Pharmacokinetics and Pharmacodynamics of K-CAB (Tegoprazan) in Healthy Male Subjects ClinicalTrials.gov · COMPLETED, 2019
- An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Tegoprazan and Non-steroidal Anti-inflammatory Drugs (NSAIDs) After Multiple Oral Dosing in Healthy Male Volunteers ClinicalTrials.gov · COMPLETED, 2020
- A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Triple Therapy With Tegoprazan, Amoxicillin and Clarithromycin in H. Pylori Positive Patients ClinicalTrials.gov · COMPLETED, 2021
- A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With Tegoprazan, Amoxicillin, and Clarithromycin in H. Pylori Positive Patients ClinicalTrials.gov · COMPLETED, 2019
- An Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetic Interaction After Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2019
- An Open-label, Randomized, Crossover Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2020
- A Double Blind, Randomized, Active-controlled, Phase 3 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis ClinicalTrials.gov · COMPLETED, 2017
- A Randomized, Open-label, Three-period Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2021
- Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study ClinicalTrials.gov · COMPLETED, 2025
- A Multi-center, Randomized, Double-blind, Double-dummy Phase III Clinical Study to Evaluate the Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori ClinicalTrials.gov · COMPLETED, 2023
- Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies as First-Line Regimens for Helicobacter Pylori Eradication: A Prospective Randomized Controlled Trial ClinicalTrials.gov · COMPLETED, 2026
- An Open-label, Randomized, Multiple-dose, Replicated Crossover Study to Evaluate Drug-drug Interaction Following Co-administration of Tegoprazan or RAPA114 With Atorvastatin in Healthy Adults ClinicalTrials.gov · COMPLETED, 2020
- An Open-label, Fixed-sequence Study to Evaluate the Drug-drug Interactions Between Tegoprazan Tablets and Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and Clarithromycin Tablets in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2023
- A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel According to CYP2C19 Genotypes in Healthy Male Volunteers ClinicalTrials.gov · COMPLETED, 2019
- Effects of Tegoprazan, Potassium-Competitive Acid Blocker, on the Gastric Emptying and Postprandial Symptoms in Healthy Humans Research Square, 2024
